Introduction
============

Gastrointestinal cancers, referring to a group of malignancies affecting the esophagus, stomach, liver, bowel, pancreas, gallbladder, and anus, are the most common cancers worldwide.[@b1-ott-8-385] There are an estimated 3.4 million new cases worldwide each year, and their mortality rates have increased gradually over the past decade.[@b1-ott-8-385] The exact mechanism of carcinogenesis is still not fully understood. It is well established that some risk factors (eg, dietary, racial, and socioeconomic) and interactions between genetic and environmental factors play important roles in the pathogenesis of cancer.[@b2-ott-8-385],[@b3-ott-8-385]

Deregulation of DNA repair is a crucial factor in the multistep process of carcinogenesis. A variety of mechanisms for DNA repair have been developed to ensure integrity of the genome in humans, and the *xeroderma pigmentosum group A (XPA)* gene is a vital component of the DNA repair machinery. The *XPA* gene is located on chromosome 9q22.3 and encodes a zinc finger DNA-binding protein participating in DNA excision repair to maintain genomic integrity.[@b4-ott-8-385] The XPA protein plays a central role in nucleotide excision repair (NER) through its interaction with replication protein A, transcription factor II H, and the excision repair cross-complementing group 1-xeroderma pigmentosum group F protein complex.[@b5-ott-8-385],[@b6-ott-8-385] In addition, XPA is involved in both global genome and transcription-coupled repair pathways,[@b7-ott-8-385] and interacts with many core repair factors during the DNA repair process.[@b8-ott-8-385] In the *XPA* gene, a polymorphic site has been identified in the 5′ untranslated region and consists of an A to G substitution in the fourth nucleotide before the ATG start codon (XPA A23G, rs 1800975). It has been shown that the polymorphism could affect protein levels in the cell.[@b9-ott-8-385],[@b10-ott-8-385] To date, a large number of molecular epidemiologic studies have been conducted to assess the role of A23G polymorphism in *XPA* gene on various types of cancers, especially those affecting the digestive system.[@b11-ott-8-385]--[@b30-ott-8-385] However, the results have been inconclusive or inconsistent. Individual studies might have been underpowered to detect the effect of this polymorphism on susceptibility to cancer. Therefore, we conducted a meta-analysis to evaluate the association between XPA A23G polymorphism and the susceptibility to digestive system cancers.

Methods
=======

Search strategy
---------------

We searched the electronic literature in the PubMed, Web of Science, China National Knowledge Infrastructure, WanFang, and VIP databases for all relevant articles. The last search update was August 30, 2014, using the search terms: "xeroderma pigmentosum group A or XPA or DNA repair gene or NER", "genetic polymorphism or polymorphisms or variant", and "digestive system cancer or gastrointestinal cancers or gastric cancer or colorectal cancer or hepatocellular carcinoma or esophageal cancer or pancreatic cancer". The search was restricted to humans without language restrictions. Additional studies were identified by a hand search of references of original or review articles on this topic. If more than one geographic or cancer type was reported in one report, each was extracted separately. If data or data subsets were published in more than one article, only the publication with the largest sample size was included.

Inclusion and exclusion criteria
--------------------------------

Studies included in this meta-analysis had to meet the following criteria: studies that evaluated the association between XPA A23G polymorphism and digestive system cancers, in a case-control study design, and had detailed genotype frequency of cases and controls or could be calculated from the article text. We excluded case-only studies, case reports, review articles, studies without raw data for the XPA A23G genotype, and repetitive publications.

Data extraction
---------------

For each study, the following data were extracted independently by two investigators: the first author's name, year of publication, country of origin, ethnicity, age, sex, source of controls, genotype methods, number of cases and controls (total and genotypes), and Hardy--Weinberg equilibrium (HWE) in controls (*P*-value). The results were compared, and disagreements were discussed among all authors and resolved with consensus. Different ethnicity was categorized as Asian and Caucasian.

Quality assessment
------------------

The quality of the eligible studies was assessed using Newcastle--Ottawa Scale (NOS), which is widely used for assessment of the quality of observational studies, including cohort or case--control studies.[@b31-ott-8-385] NOS, consisting of three parts (selection, comparability, and exposure), is a star-rewarded scale. A total of four, two, and three stars, respectively, will be rewarded if the criteria are met. A study with seven or more stars was categorized as high quality, otherwise, the study was categorized as low quality.

Statistical analysis
--------------------

HWE was evaluated for each study using an Internet-based HWE calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The risk of digestive system cancers associated with XPA A23G polymorphism was estimated for each study by odds ratio (OR) and 95% confidence interval (CI). The most common G allele was considered the reference genotype and the rare A allele was examined as the variant in this analysis. Four different ORs were calculated: the dominant model (AG + AA versus GG), the recessive model (AA versus AG + GG), heterozygote comparison (AG versus GG), and homozygote comparison (AA versus GG). A *χ*^2^-test-based *Q* statistic test was performed to assess between-study heterogeneity.[@b32-ott-8-385] We also quantified the effect of heterogeneity by *I*^2^ test. When a significant *Q* test (*P*\>0.1) or *I*^2^\<50% indicated homogeneity across studies, the fixed effects model was used,[@b33-ott-8-385] or else the random effects model was used.[@b34-ott-8-385] We then performed stratification analyses on ethnicity, tumor type, and source of control. Analysis of sensitivity was performed to evaluate the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the individual data set on the pooled OR. Finally, potential publication bias was investigated using Begg's funnel plot and Egger's regression test.[@b35-ott-8-385],[@b36-ott-8-385] *P*\<0.05 was considered to be statistically significant. All analyses were performed using the Cochrane Collaboration RevMan 5.2 and Stata package version 12.0 (Stata Corp, College Station, TX, USA).

Results
=======

Study characteristics
---------------------

After an initial search, a total of 101 published articles relevant to the topic were identified. According to the inclusion criteria, 20 studies[@b11-ott-8-385]--[@b30-ott-8-385] with full text were included in this meta-analysis and 81 studies were excluded. The flow chart for study selection is summarized in [Figure 1](#f1-ott-8-385){ref-type="fig"}. Because the study by Huang et al[@b17-ott-8-385] included two types of cancer, we treated them separately in this meta-analysis; three articles[@b27-ott-8-385]--[@b29-ott-8-385] that had overlapped study data were also excluded. Moreover, we excluded one study[@b30-ott-8-385] because it did not present detailed genotyping information. Therefore, as shown in [Table 1](#t1-ott-8-385){ref-type="table"}, there were 18 case-control studies[@b11-ott-8-385]--[@b26-ott-8-385] with 4,170 cases and 6,929 controls concerning XPA A23G polymorphism. Of the 18 eligible studies, nine studies[@b12-ott-8-385],[@b14-ott-8-385],[@b15-ott-8-385],[@b17-ott-8-385],[@b20-ott-8-385],[@b22-ott-8-385],[@b24-ott-8-385]--[@b26-ott-8-385] involved esophageal cancers, four studies[@b11-ott-8-385],[@b17-ott-8-385],[@b21-ott-8-385] involved gastric cancers, four[@b13-ott-8-385],[@b16-ott-8-385],[@b18-ott-8-385],[@b19-ott-8-385] involved colorectal cancers, and one[@b23-ott-8-385] involved hepatocellular carcinoma. Two ethnicities were addressed: eleven studies[@b11-ott-8-385],[@b12-ott-8-385],[@b14-ott-8-385],[@b17-ott-8-385],[@b20-ott-8-385],[@b23-ott-8-385]--[@b26-ott-8-385] were conducted in Asian populations and seven studies[@b13-ott-8-385],[@b15-ott-8-385],[@b16-ott-8-385],[@b18-ott-8-385],[@b19-ott-8-385],[@b21-ott-8-385],[@b22-ott-8-385] in Caucasian populations. The distribution of genotypes in the controls was consistent with HWE for all selected studies. The quality of all eligible studies was categorized as high except for one study.[@b20-ott-8-385]

Quantitative data synthesis
---------------------------

As shown in [Table 2](#t2-ott-8-385){ref-type="table"}, overall no significant association was found between XPA A23G polymorphism and the risk of digestive system cancers (dominant model: OR 0.89, 95% CI 0.74--1.08; recessive model: OR 0.94, 95% CI 0.74--1.20; GA versus GG, OR 0.89, 95% CI 0.77--1.03; and AA versus GG, OR 0.87, 95% CI 0.64--1.19, [Figure 2](#f2-ott-8-385){ref-type="fig"}).

In subgroup analysis by ethnicity, there was no significant association between XPA A23G polymorphism and the risk of digestive system cancers in either Asians or Caucasians ([Table 2](#t2-ott-8-385){ref-type="table"}, [Figure 3](#f3-ott-8-385){ref-type="fig"}).

In stratified analysis based on tumor type, we also failed to detect any association between XPA A23G polymorphism and the risk of esophageal, gastric, or colorectal cancers. In addition, only one study focused on hepatocellular carcinoma, and the results showed no association between XPA A23G polymorphism and the risk of hepatocellular carcinoma ([Table 2](#t2-ott-8-385){ref-type="table"}, [Figure 4](#f4-ott-8-385){ref-type="fig"}).

When the analysis was stratified by source of control, we found that XPA A23G polymorphism was associated with a decreased risk of digestive system cancers in population-based models (GA versus GG, OR 0.86, 95% CI 0.77--0.96), but not in other genetic models or hospital-based populations ([Table 2](#t2-ott-8-385){ref-type="table"}). However, it is worth noting that there was moderate heterogeneity (*I*^2^=40%) in the subgroup analysis; when the study by Zhen et al was excluded, the heterogeneity disappeared (*I*^2^=0%), and the pooled results showed no significant differences in genotype distribution between digestive system cancer cases and controls (OR 0.92, 95% CI 0.82--1.04). Therefore, the results that included the study by Zhen et al should be cautiously interpreted.

Heterogeneity and sensitivity analyses
--------------------------------------

Substantial heterogeneity was observed between studies for the association between XPA A23G polymorphism and digestive system cancer risk in all genetic models (dominant model: *I*^2^=73%, *P*\<0.00001; recessive model: *I*^2^=83%, *P*\<0.00001; GA versus GG, *I*^2^=52%, *P*=0.005; and AA versus GG, *I*^2^=83%, *P*\<0.00001). We therefore assessed the source of heterogeneity by ethnicity, tumor type, and source of control. The heterogeneity was partly decreased or removed for gastric cancers, colorectal cancers, Caucasians, and population-based studies. However, there was still significant heterogeneity for esophageal cancer, Asians, and hospital-based populations. Sensitivity analysis was then performed to evaluate the stability of the results. The statistical significance of the results was not altered when any single study was omitted, confirming the stability of the findings.

Publication bias
----------------

We used the Begg's funnel plot and Egger's test to address potential publication bias in the available literature. The shape of the funnel plots did not reveal any evidence of funnel plot asymmetry ([Figure 5](#f5-ott-8-385){ref-type="fig"}). Egger's test also showed that there was no statistical significance for the evaluation of publication bias (dominant model: *P*=0.703; GA versus GG, *P*=0.792; AA versus GG, *P*=0.895; recessive model, *P*=0.678).

Discussion
==========

The evidence suggests that reduced DNA repair capacity may lead to genetic instability and carcinogenesis, genes involved in DNA repair have been proposed as candidate cancer susceptibility genes.[@b37-ott-8-385] The NER pathway may be important in modulating susceptibility to cancer, because it is the primary mechanism for repair of a wide variety of types of DNA damage.[@b38-ott-8-385]--[@b40-ott-8-385] There are several core genes in the NER pathway (eg, ERCC1, XPA, XPB/ERCC3, XPC, XPD/ERCC2, XPE/DDB1, XPF/ERCC4, and XPG/ERCC5). Of these, the *XPA* gene is one of the central players, with a vital role in repairing DNA damage and maintaining the integrity of the genome.[@b4-ott-8-385] Recently, A23G polymorphism of the *XPA* gene was reported to confer a risk of digestive system cancers. Furthermore, a number of epidemiological studies have evaluated the association between this polymorphism and risk of digestive system cancers, but the results remain inconclusive. Dong et al[@b11-ott-8-385] and Guo et al[@b14-ott-8-385] reported that the XPA A23G polymorphism was associated with a decreased risk of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a high-incidence population in northern China; however, in a study from the USA, Pan et al[@b22-ott-8-385] suggested that the heterozygous AG genotype of the XPA 5′ untranslated region was associated with a 2.11-fold increased risk, and the increased risk reached 3.10-fold for the homozygous variant GG genotype in esophageal cancer. Furthermore, Gil et al[@b13-ott-8-385] found that the XPA A23G polymorphism may be unrelated to the risk of sporadic colorectal cancer; similarly, Hansen et al[@b16-ott-8-385] failed to detect an association between the polymorphism and risk of colorectal cancer in a Danish population. These inconsistent results may be attributed to differences in genetic backgrounds, environmental factors, and other factors.

A recent meta-analysis[@b41-ott-8-385] evaluated the association between XPA A23G polymorphism and cancer risk, and reported that this polymorphism is associated with an increased lung cancer risk and may be a low-penetrant risk factor for development of cancer in people of Asian ethnicity. Subsequently, Liu et al[@b42-ott-8-385] conducted another meta-analysis to assess the association between A23G polymorphism and risk of cancer, and suggested that the XPA A23G G allele is a low-penetrant risk factor for development of cancer. However, only few studies focusing on digestive system cancers (eight and nine studies, respectively) were included in the above meta-analysis, and due to the limited study number, further analyses was not conducted. Compared with those studies, we conducted a more comprehensive literature search in different databases (including Web of Science, China National Knowledge Infrastructure, WanFang, and VIP) and included several additional studies,[@b17-ott-8-385],[@b19-ott-8-385],[@b20-ott-8-385],[@b23-ott-8-385]--[@b26-ott-8-385] which allowed for a larger number of subjects and more precise risk estimation. In this meta-analysis, we pooled 18 studies to explore the association between A23G polymorphism and risk of gastrointestinal cancers. The results demonstrated that XPA A23G polymorphism is not associated with digestive system cancer risk.

The outcomes from meta-analysis can be affected by several factors, such as ethnicity, cancer origin, and control selection. Therefore, subgroup analyses were conducted. In this study, stratification by ethnicity, tumor type, and source of control revealed no significant association. The results seem to contradict the previous meta-analyses. The discrepancies are probably due to the small size of the A23G polymorphism in determining susceptibility to digestive system cancers in the previous meta-analyses. Moreover, the biological mechanisms of the *XPA* gene in carcinogenesis are complicated, and may be mediated by the activities of multiple genes (such as ERCC1 and XPF) in the NER pathway, the function of which may be different in digestive system cancers than in other cancers. In addition, cancer is a multifactorial disease that results from complex interactions between many environmental and genetic factors. Therefore, when we only consider suspected gene polymorphism in digestive system cancers and ignore the role of other genes and environmental factors, we might fail to conclude a real association.

Two significant issues should be addressed in this study, ie, heterogeneity and publication bias, which may influence the results of a meta-analysis. We did not detect a significant publication bias in this meta-analysis, suggesting that our results are reliable. With regard to heterogeneity, in this meta-analysis, heterogeneity was found in overall comparison under all genetic models, when stratified by ethnicity, tumor type, and source of control, the heterogeneity was partly decreased or removed among gastric and colorectal cancers, Caucasians, and population-based subgroups. However, heterogeneity still existed for esophageal cancer, Asians, and hospital-based populations. In addition, when the study by Zhen et al was excluded, the heterogeneity decreased. Our results suggest that the ethnic background, different types of tumor, and the particular study might be the source of heterogeneity. Then sensitivity analyses were conducted by successively excluding one study, the estimated pooled odd ratio changed quite little, indicating that the results of this meta-analysis were stable.

This meta-analysis has limitations that must be acknowledged. First, all case-control studies included were done in Asians and Caucasians, so our results may be applicable only to these populations. More studies on Africans and other ethnic groups are needed. Second, the controls included in our analysis were selected variously from either population-based or hospitals. Therefore, misclassification bias was possible because these studies may have included control groups that have different risks for developing digestive system cancers. Third, our results were based on unadjusted estimates, without adjustment for family history or other risk factors, which may cause serious confounding bias.

Conclusion
==========

In summary, this meta-analysis suggests that XPA A23G polymorphism is not associated with a risk of digestive system cancers. However, large and well-designed studies taking into consideration gene--gene and gene--environment interactions are warranted to validate our findings.

**Disclosure**

The authors report no conflicts of interest in this work.

![Flow chart showing study selection procedure.](ott-8-385Fig1){#f1-ott-8-385}

![Forest plots of odds ratios for the association of XPA A23G polymorphism and digestive system cancer risk (dominant model).\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel method.](ott-8-385Fig2){#f2-ott-8-385}

![Subgroup analysis by ethnicity of odds ratios for the association of XPA A23G polymorphism and digestive system cancer risk (dominant model).\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel method.](ott-8-385Fig3){#f3-ott-8-385}

![Subgroup analysis by tumor type of odds ratios for the association of XPA A23G polymorphism and digestive system cancer risk (dominant model).\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel method.](ott-8-385Fig4){#f4-ott-8-385}

![Begg's funnel plot for publication bias (GA versus GG).](ott-8-385Fig5){#f5-ott-8-385}

###### 

Characteristics of studies included in the meta-analysis

  Study                           Year                                            Country                      Ethnicity   Age, years      Sex (male/female)   Cancer type   Source of controls   Genotype methods   Genotype (case/control)   *P* ~HWE~   NOS                                             
  ------------------------------- ----------------------------------------------- ---------------------------- ----------- --------------- ------------------- ------------- -------------------- ------------------ ------------------------- ----------- --------- --------- --------- --------- ------- ---
  Dong et al[@b11-ott-8-385]      2008                                            People's Republic of China   Asian       60.4±8.30       60.4±8.42           165/88        385/227              Gastric            PB                        PCR--RFLP   253/612   47/128    120/322   86/162    0.169   8
  Feng et al[@b12-ott-8-385]      2008                                            People's Republic of China   Asian       59.09±8.43      58.81±8.58          125/71        130/71               Esophageal         HB                        PCR--RFLP   196/201   28/56     83/91     85/54     0.181   7
  Gil et al[@b13-ott-8-385]       2012                                            Poland                       Caucasian   63.22±11.36     74.89±7.63          NR            NR                   Colorectal         HB                        PCR--RFLP   100/133   26/50     58/67     16/16     0.369   8
  Guo et al[@b14-ott-8-385]       2008                                            People's Republic of China   Asian       60.0±9.33       60.4±8.42           218/109       385/227              Esophageal         PB                        PCR--RFLP   327/612   65/128    139/322   123/162   0.169   8
  Hall et al[@b15-ott-8-385]      2007                                            Europe                       Caucasian   NR              NR                  NR            NR                   Esophageal         HB                        TaqMan      171/974   75/398    81/451    15/125    0.875   9
  Hansen et al[@b16-ott-8-385]    2007                                            Denmark                      Caucasian   59 (51--64)     56 (50--63)         219/178       434/366              Colorectal         PB                        NR          394/788   176/339   187/359   31/90     0.731   8
  Huang et al[@b17-ott-8-385]     2007[a](#tfn2-ott-8-385){ref-type="table-fn"}   People's Republic of China   Asian       NR              NR                  112/38        301/101              Esophageal         PB                        PCR--RFLP   150/402   22/32     69/160    59/210    0.843   7
  Huang et al[@b17-ott-8-385]     2007[b](#tfn3-ott-8-385){ref-type="table-fn"}   People's Republic of China   Asian       NR              NR                  116/29        130/50               Cardiac            PB                        PCR--RFLP   145/180   20/13     60/55     65/112    0.097   7
  Huang et al[@b17-ott-8-385]     2007[c](#tfn4-ott-8-385){ref-type="table-fn"}   People's Republic of China   Asian       NR              NR                  111/35        130/50               Gastric            PB                        PCR--RFLP   146/180   12/13     57/55     77/112    0.097   7
  Jelonek et al[@b18-ott-8-385]   2010                                            Poland                       Caucasian   NR              NR                  NR            NR                   Colorectal         HB                        PCR--RFLP   66/133    29/46     33/70     4/17      0.225   8
  Joshi et al[@b19-ott-8-385]     2009                                            USA                          Caucasian   60.0±11.3       59.3±11.8           NR            NR                   Colorectal         PB                        TaqMan      302/349   136/149   133/170   33/30     0.056   8
  Liu et al[@b20-ott-8-385]       2007                                            People's Republic of China   Asian       63.67±9.58      62.50±9.39          56/41         56/41                Esophageal         PB                        PCR--RFLP   96/96     11/11     35/47     50/38     0.535   6
  Palli et al[@b21-ott-8-385]     2010                                            Italy                        Caucasian   68.8±9.9        55.5±7.0            177/137       270/278              Gastric            PB                        TaqMan      284/523   134/249   115/215   35/59     0.227   8
  Pan et al[@b22-ott-8-385]       2009                                            USA                          Caucasian   63.13±10.60     62.91±10.38         343/44        397/65               Esophageal         HB                        PCR--RFLP   380/458   179/151   166/219   35/88     0.589   8
  Xie et al[@b23-ott-8-385]       2007                                            People's Republic of China   Asian       49.1 (17--80)   48.6 (28--79)       377/57        384/96               Hepatocellular     PB                        PCR--RFLP   415/479   139/144   203/219   73/116    0.071   7
  Zhang et al[@b24-ott-8-385]     2006                                            People's Republic of China   Asian       NR              NR                  NR            NR                   Esophageal         HB                        PCR--RFLP   206/206   33/44     82/96     91/66     0.412   7
  Zhen et al[@b25-ott-8-385]      2012                                            People's Republic of China   Asian       NR              NR                  237/114       258/142              Esophageal         PB                        PCR--RFLP   351/400   99/53     145/188   107/159   0.826   7
  Zhu et al[@b26-ott-8-385]       2008                                            People's Republic of China   Asian       61.03           60.77               105/83        126/77               Esophageal         PB                        PCR--SSCP   188/203   50/52     69/88     69/63     0.063   7

**Notes:** Age is expressed either as mean ± standard deviation or median (interquartile range).

Esophageal study;

cardiac study;

gastric study.

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; PCR--RFLP, polymerase chain reaction--restriction fragment length polymorphism; PCR--SSCP, polymerase chain reaction--single strand conformation polymorphism; PB, population-based; HB, hospital-based; NR, not reported; NOS, Newcastle--Ottawa Scale.

###### 

Summary of odds ratios for the risk of the XPG Asp1104His polymorphism and gastrointestinal cancers

  Variables               N[a](#tfn6-ott-8-385){ref-type="table-fn"}   Dominant model      Recessive model   GA versus GG   AA versus GG                                                                                          
  ----------------------- -------------------------------------------- ------------------- ----------------- -------------- ------------------- ----------- ---- ------------------- ------- ---- ------------------- ----------- ----
  Total                   18                                           0.89 (0.74--1.08)   \<0.00001         73             0.94 (0.74--1.20)   \<0.00001   83   0.89 (0.77--1.03)   0.005   52   0.87 (0.64--1.19)   \<0.00001   83
  **Ethnicity**                                                                                                                                                                                                                   
  Asian                   11                                           0.90 (0.66--1.21)   \<0.00001         78             1.04 (0.77--1.41)   \<0.00001   86   0.87 (0.68--1.10)   0.007   59   0.95 (0.62--1.44)   \<0.00001   86
  Caucasian               7                                            0.88 (0.71--1.10)   0.007             66             0.78 (0.55--1.13)   0.006       67   0.90 (0.79--1.03)   0.09    45   0.76 (0.49--1.18)   0.0004      76
  **Tumor type**                                                                                                                                                                                                                  
  Esophageal              9                                            0.87 (0.61--1.23)   \<0.00001         84             1.04 (0.71--1.52)   \<0.00001   88   0.81 (0.62--1.06)   0.002   68   0.89 (0.52--1.54)   \<0.00001   90
  Gastric                 4                                            0.99 (0.80--1.22)   0.22              32             0.86 (0.53--1.41)   0.0006      83   0.98 (0.78--1.23)   0.85    0    0.88 (0.52--1.50)   0.02        69
  Colorectal              4                                            0.96 (0.80--1.14)   0.14              45             0.91 (0.56--1.47)   0.08        56   0.98 (0.82--1.17)   0.21    33   0.92 (0.52--1.62)   0.04        63
  Hepatocellular          1                                            0.85 (0.64--1.13)   NA                NA             0.67 (0.48--0.93)   NA          NA   0.96 (0.71--1.30)   NA      NA   0.65 (0.45--0.95)   NA          NA
  **Source of control**                                                                                                                                                                                                           
  PB                      12                                           0.83 (0.69--1.00)   0.002             63             0.93 (0.72--1.20)   \<0.00001   81   0.86 (0.77--0.96)   0.08    40   0.81 (0.60--1.11)   \<0.00001   77
  HB                      6                                            1.09 (0.69--1.73)   \<0.00001         85             0.96 (0.52--1.76)   \<0.00001   87   1.04 (0.74--1.47)   0.005   70   1.00 (0.44--2.27)   \<0.00001   90

**Notes:**

Number of comparisons;

test for heterogeneity.

**Abbreviations:** CI, confidence interval; HB, hospital-based; NA, not applicable; OR, odds ratio; PB, population-based.
